Epidemiological trends and survival of oropharyngeal cancer in a high HPV-prevalent area: A Danish population-based study from 2000 to 2020.
HPV
OPSCC
human papillomavirus
oropharyngeal cancer
p16
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
17 Jul 2024
17 Jul 2024
Historique:
revised:
06
06
2024
received:
02
04
2024
accepted:
19
06
2024
medline:
17
7
2024
pubmed:
17
7
2024
entrez:
17
7
2024
Statut:
aheadofprint
Résumé
Denmark, alongside other Scandinavian countries, the United States, Canada, and the United Kingdom, has high prevalence of human papillomavirus (HPV). Our oropharyngeal squamous cell carcinoma (OPSCC) database includes all diagnosed cases in Eastern Denmark during a period of more than two decades. We investigated the incidence, survival, and recurrence of patients with OPSCC with combined p16- and HPV testing covering a consecutive 21-year period. Age-adjusted incidence rate (AAIR) per 100,000, survival models, and Cox proportional-hazards model were employed. Two thousand eight hundred thirty-four patients were included (57.5% HPV positive (HPV+)/p16 positive (p16+), 33.7% HPV negative (HPV-)/p16 negative (p16-), 4% HPV+/p16-, and 4.8% HPV-/p16+). The AAIR for all patients increased from 1.8 to 5.1 per 100,000 from 2000 to 2020 linked to an increasing AAIR of HPV+/p16+ OPSCCs from 0.9 to 3.5 per 100,000 from 2000 to 2020. The AAIR for the HPV-/p16- OPSCCs decreased from 1.6 to 1.4 from 2017 to 2020. HPV+/p16+ OPSCCs had a higher 5-year overall survival (OS) of 79.2% compared to the other subgroups (HPV+/p16- OS: 50.4%; HPV-/p16+ OS: 49.4%; HPV-/p16- OS: 35.1%). The AAIR of the total OPSCC group increased from year 2000 to 2020, driven by a rise in the HPV+/p16+ group. A decreasing incidence rate was observed for the HPV-/p16- OPSCCs from 2017 to 2020. The OS for HPV+/p16+ OPSCCs was significantly higher compared to all other HPV/p16 subgroups. Therefore, we recommend testing for combined HPV and p16 status in patients with OPSCC when selecting patients for clinical trials, especially in case of de-escalating/escalating.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Näsman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral‐induced carcinoma? Int J Cancer. 2009;125(2):362‐366. doi:10.1002/ijc.24339
Schache AG, Powell NG, Cuschieri KS, et al. HPV‐related oropharynx cancer in the United Kingdom: an evolution in the understanding of disease etiology. Cancer Res. 2016;76(22):6598‐6606. doi:10.1158/0008‐5472.CAN‐16‐0633
Zamani M, Grønhøj C, Jensen DH, et al. The current epidemic of HPV‐associated oropharyngeal cancer: an 18‐year Danish population‐based study with 2,169 patients. Eur J Cancer. 2020;134:52‐59. doi:10.1016/j.ejca.2020.04.027
Jensen JS, Jensen DH, Grønhøj C, et al. Incidence and survival of oropharyngeal cancer in Denmark: a nation‐wide, population‐based study from 1980 to 2014. Acta Oncol. 2018;57(2):269‐275. doi:10.1080/0284186X.2017.1390251
Carlander ALF, Bendtsen SK, Rasmussen JH, et al. Clinical and prognostic differences in oropharyngeal squamous cell carcinoma in USA and Denmark, two HPV high‐prevalence areas. Eur J Cancer. 2024;202(February):113983. doi:10.1016/j.ejca.2024.113983
Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. Meta‐analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2010;2(1):1‐11. doi:10.1186/1758‐3284‐2‐15
Mork J, Lie AK, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous‐cell carcinoma of the head and neck. N Engl J Med. 2001;344(15):1125‐1131. doi:10.1056/nejm200104123441503
Gillison ML, Shah KV. Human papillomavirus‐associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers. Curr Opin Oncol. 2001;13(3):183‐188. doi:10.1097/00001622‐200105000‐00009
Taberna M, Mena M, Pavón MA, Alemany L, Gillison ML, Mesía R. Human papillomavirus‐related oropharyngeal cancer. Ann Oncol. 2017;28(10):2386‐2398. doi:10.1093/annonc/mdx304
Dahlstrom KR, Bell D, Hanby D. Socioeconomic characteristics of patients with oropharyngeal carcinoma according to tumor HPV status, patient smoking status, and sexual behavior. Oral Oncol. 2015;51(9):832‐838. doi:10.1016/j.oraloncology.2015.06.005
Swartz LK, Swiecicki PL. Head and neck cancers. J Natl Compr Canc Netw. Version 3. 2024;185‐195.
Grønhøj C, Jensen DH, Dehlendorff C, et al. Development and external validation of nomograms in oropharyngeal cancer patients with known HPV‐DNA status: a European Multicentre Study (OroGrams). Br J Cancer. 2018;118(12):1672‐1681. doi:10.1038/s41416‐018‐0107‐9
Mirghani H, Casiraghi O, Guerlain J, et al. Diagnosis of HPV driven oropharyngeal cancers: comparing p16 based algorithms with the RNAscope HPV‐test. Oral Oncol. 2016;62:101‐108. doi:10.1016/j.oraloncology.2016.10.009
Grønhøj Larsen C, Gyldenløve M, Jensen DH, et al. Correlation between human papillomavirus and p16 overexpression in oropharyngeal tumours: a systematic review. Br J Cancer. 2014;110(6):1587‐1594. doi:10.1038/bjc.2014.42
Jakobsen KK, Carlander ALF, Bendtsen SK, et al. Diagnostic accuracy of hpv detection in patients with oropharyngeal squamous cell carcinomas: a systematic review and meta‐analysis. Viruses. 2021;13(9):1692. doi:10.3390/v13091692
Mehanna H, Taberna M, vonBuchwald C, et al. Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG‐EPIC‐OPC): a multicentre, multinational, individual patient data analysis. Lancet Oncol. 2023;24:239‐251. doi:10.1016/S1470‐2045(23)00013‐X
Carlander ALF, Grønhøj Larsen C, Jensen DH, et al. Continuing rise in oropharyngeal cancer in a high HPV prevalence area: a Danish population‐based study from 2011 to 2014. Eur J Cancer. 2017;70:75‐82. doi:10.1016/j.ejca.2016.10.015
Sundhedsstyrelsen. Pakkeforløb for Hoved‐Og Halskraeft For Fagfolk. 2020 www.sst.dk
Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:1‐24. doi:10.1016/j.jbi.2019.103208
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata‐driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377‐381. doi:10.1016/j.jbi.2008.08.010
Sundhedsstyrelsen. Notat om Sundhedsstyrelsens alkoholudmeldinger. 2022; 1–5.
Channir HI, Bendtsen SK, Melchior LC, et al. Validation of the VisionArray® Chip assay for HPV DNA testing in histology specimens of oropharyngeal squamous cell carcinoma. Head Neck Pathol. 2024;18(1):27. doi:10.1007/s12105‐024‐01628‐3
Brierley JD, Gospodarowicz MK, Wittekind C, eds. TNM Classification of Malignant Tumours. 8th ed. Wiley‐Blackwell; 2016 https://www.wiley.com/en-gb/TNM+Classification+of+Malignant+Tumours%2C+8th+Edition-p-9781119263579
Haeggblom L, Attoff T, Yu J, et al. Changes in incidence and prevalence of human papillomavirus in tonsillar and base of tongue cancer during 2000‐2016 in the Stockholm region and Sweden. Head Neck. 2019;41(6):1583‐1590. doi:10.1002/hed.25585
SSI. Vaccination mod human papilloma virus (HPV). Accessed March 3, 2023. https://www.ssi.dk/vaccinationer/boernevaccination/vaccination-mod-livmoderhalskraeft
Kræftens Bekæmpelse. Hvad er HPV‐vaccination? Accessed March 27, 2024. https://www.cancer.dk/forebyg-kraeft/hpv-vaccination/hvad-er-hpv-vaccination/#Hvem_får_tilbudt_gratis_HPV-vaccination?
Garset‐Zamani M, vonBuchwald C, Karevold G, et al. An HPV‐vaccinated patient with human papillomavirus–positive oropharyngeal squamous cell carcinoma. JAMA Otolaryngol–Head Neck Surg. 2023;149(1):92. doi:10.1001/jamaoto.2022.3762
Kræftens Bekæmpelse. Voksnes rygevaner. Accessed May 9, 2023. https://www.cancer.dk/forebyg/undga‐roeg‐og‐rygning/fakta‐om‐rygning/voksnes‐rygevaner/
Kræftens Bekæmpelse. Rygningens historie i Danmark. Accessed May 9, 2023. https://www.cancer.dk/skole/viden-om-kraeft/kan-man-undgaa-kraeft/undgaa-rygning/regler-om-rygning/
Kræftens Bekæmpelse. Fald i kræftdiagnoser under corona ramte især tre store kræftsygdomme. 2022 Accessed September 28, 2023. https://www.cancer.dk/nyheder/fald‐i‐kraeftdiagnoser‐under‐corona‐ramte‐isaer‐tre‐store‐kraeftsygdomme/
Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24‐35. doi:10.1056/NEJMoa0912217
UICC. TNM classification of malignant tumors ‐ 8th edition. Changes between the 7th and 8th editions. 2018.
Rasmussen JH, Grønhøj C, Håkansson K, et al. Risk profiling based on p16 and HPV DNA more accurately predicts location of disease relapse in patients with oropharyngeal squamous cell carcinoma. Ann Oncol. 2019;30(4):629‐636. doi:10.1093/annonc/mdz010
Jakobsen KK, Bendtsen SK, Pallisgaard N, et al. Liquid biopsies with circulating plasma HPV–DNA measurements—a clinically applicable surveillance tool for patients with HPV‐positive oropharyngeal cancer. Clin Cancer Res. 2023;29(19):3914‐3923. doi:10.1158/1078‐0432.CCR‐23‐1064
Garnaes E, Kiss K, Andersen L, et al. A high and increasing HPV prevalence in tonsillar cancers in eastern Denmark, 2000‐2010: the largest registry‐based study to date. Int J Cancer. 2015;136(9):2196‐2203. doi:10.1002/ijc.29254
Garnaes E, Kiss K, Andersen L, et al. Increasing incidence of base of tongue cancers from 2000 to 2010 due to HPV: the largest demographic study of 210 Danish patients. Br J Cancer. 2015;113(1):131‐134. doi:10.1038/bjc.2015.198